<DOC>
	<DOCNO>NCT00443976</DOCNO>
	<brief_summary>RATIONALE : Aurora kinase inhibitor AT9283 ( AT9283 ) may stop growth cancer cell block enzymes need cell growth . PURPOSE : This phase I trial study side effect best dose AT9283 treat patient advanced metastatic solid tumor non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Aurora Kinase Inhibitor AT9283 Treating Patients With Advanced Metastatic Solid Tumors Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose recommend phase II dose Aurora kinase inhibitor AT9283 ( AT9283 ) patient incurable advanced metastatic solid tumor non-Hodgkin 's lymphoma . - Determine safety , tolerability , toxicity profile , dose-limiting toxicity , pharmacokinetic profile drug patient . - Correlate toxicity profile pharmacokinetics drug patient . - Assess , preliminarily , evidence antitumor activity drug patient . - Determine pharmacodynamic activity drug patient correlate biological endpoint . OUTLINE : This open-label , dose-escalation , multicenter study . Patients receive Aurora kinase inhibitor AT9283 ( AT9283 ) IV 24 hour day 1 8 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos AT9283 maximum tolerate dose ( MTD ) determine . The MTD define dose least 2 3 2 6 patient experience dose-limiting toxicity . The dose preceding MTD recommend phase II dose ( RPTD ) . Up 8 additional patient treat RPTD . Patients treat RPTD undergo skin tumor tissue biopsy blood collection baseline day 2 and/or 3 . Samples examine pharmacokinetic pharmacodynamic analysis , include immunohistochemistry , immunocytochemistry , western blotting , immunoenzyme technique , flow cytometry , reverse transcriptase-polymerase chain reaction , biological marker . After completion study treatment , patient follow 4 week every 3 month disease progression . PROJECTED ACCRUAL : Up 30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm diagnosis 1 following : Advanced and/or metastatic solid tumor Advanced metastatic nonHodgkin 's lymphoma refractory standard therapy Clinically radiologically document disease No tumor marker elevation evidence disease No untreated brain meningeal metastasis Treated stable brain metastasis allow provide asymptomatic require steroid PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤ 1.25 time upper limit normal ( ULN ) OR creatinine clearance ≥ 50 mL/min Bilirubin normal ALT AST ≤ 2 time ULN ( ≤5 time ULN liver metastasis present ) Not pregnant nursing Negative pregnancy test Fertile patient must use two effective method contraception No untreated uncontrolled hypertension , cardiovascular condition , symptomatic cardiac dysfunction No active uncontrolled infection No serious illness medical condition would preclude study treatment PRIOR CONCURRENT THERAPY : At least 2 week since prior major surgery recover At least 3 week since prior palliative radiotherapy recover Lowdose , nonmyelosuppressive radiotherapy may allow At least 3 week since prior chemotherapy solid tumor recover No 2 prior cytotoxic chemotherapy regimens metastatic disease At least 4 week since prior steroid No limitation prior therapy patient nonHodgkin 's lymphoma Prior hormonal , immunologic , biologic signal transduction inhibitor therapy allow No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
</DOC>